Bruniera F R, Ferreira F M, Saviolli L R M, Bacci M R, Feder D, da Luz Gonçalves Pedreira M, Sorgini Peterlini M A, Azzalis L A, Campos Junqueira V B, Fonseca F L A
Discipline of Pharmacology, Morphology Department, Faculdade de Medicina do ABC, Santo André, Brazil.
Eur Rev Med Pharmacol Sci. 2015 Feb;19(4):694-700.
Vancomycin (VCM) is a tricyclic glycopeptide antibiotic produced by Streptococcus orientalis. Widely used in hospitals, it is indicated to fight severe infections caused by Gram-positive bacteria, especially with the advent of MRSA (methicillin-resistant Staphylococcus aureus), penicillin-resistant pneumococci among others. Furthermore, it is indicated for the treatment of patients allergic to penicillins and cephalosporins. Dose recommendations, dilution rates and types of infusion are controversial and also result in toxic effects. Aim of this paper was to perform a literature review showing the therapeutic and adverse effects of vancomycin.
This is a literature review of recent articles published on MEDLINE and SciELO databases in English, Portuguese and Spanish.
The main adverse effects of vancomycin are: hypotension, phlebitis, nephrotoxicity, ototoxicity, hypersensitivity reactions, red man syndrome, neutropenia, chills, fever, interstitial nephritis.
The use of vancomycin is still very common; however, inadequate doses and prolonged therapy pose a risk of increasing minimum inhibitory concentrations (MICs), resulting in subtherapeutic levels, treatment failures and toxicity. Therefore, further studies should be conducted to optimize the administration of vancomycin, monitoring treatments from the beginning in order to ensure a safe and effective use of the drug.
万古霉素(VCM)是一种由东方链球菌产生的三环糖肽抗生素。它在医院中广泛使用,用于对抗由革兰氏阳性菌引起的严重感染,尤其是随着耐甲氧西林金黄色葡萄球菌(MRSA)、耐青霉素肺炎球菌等的出现。此外,它还用于治疗对青霉素和头孢菌素过敏的患者。剂量推荐、稀释率和输注类型存在争议,并且还会导致毒性作用。本文的目的是进行一项文献综述,展示万古霉素的治疗作用和不良反应。
这是一项对在MEDLINE和SciELO数据库上以英文、葡萄牙文和西班牙文发表的近期文章的文献综述。
万古霉素的主要不良反应有:低血压、静脉炎、肾毒性、耳毒性、过敏反应、红人综合征、中性粒细胞减少、寒战、发热、间质性肾炎。
万古霉素的使用仍然非常普遍;然而,剂量不足和治疗时间延长会增加最低抑菌浓度(MIC)的风险,导致治疗水平不足、治疗失败和毒性。因此,应进行进一步研究以优化万古霉素的给药方式,从一开始就监测治疗情况,以确保安全有效地使用该药物。